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Hormones and breast cancer: controlling the danger within
For the first half of the 20th century, the effects of sex hormones on breast 
cancer were poorly understood due to the lack of an animal model. In 1959, 
Charles Huggins devised a method to induce hormone-responsive mammary 
cancers in rats. The model paved the way for new treatment and prevention 
strategies for breast cancer.
A hormonal paradox
In 1896, a physician named George 
Beatson controlled the growth of 
mammary tumors in women by sim-
ply removing their ovaries (1); he thus 
provided the first connection between 
breast cancer and the secretions of re-
productive organs. But a lack of ovarian 
function did not guarantee a cancer-
free life—breast cancer also occurred in 
men and older women.
The identification of the ovarian 
hormone estrogen introduced a new 
paradox into this still murky area. High 
doses of estrogen could actually shrink 
breast tumors in some women. Also, 
these contrasting treatments—the removal 
of estrogen sources and the adminis-
tration of high-dose estrogen—were 
effective in only one in three women. 
Further research to resolve these issues 
was impossible, as mammary cancers in 
existing mouse models were seldom 
responsive to hormone treatment.
The perfect model
By the early 1950s, Huggins, who had 
founded the Ben May Cancer Research 
Center at the University of Chicago, was 
already one of the leading experts on the 
hormonal control of cancer. His discov-
ery that prostate tumors in male dogs 
could be reduced by castration or by es-
trogen injection had led to prostate cancer 
control in a majority of male patients (2).
Huggins next turned to breast can-
cer and the search for a good disease 
model. A few years earlier, a researcher 
had serendipitously discovered that rats 
of the Wistar strain sometimes devel-
oped mammary cancers when fed with a 
known carcinogen called 3-methylchol-
anthrene (3-MC) for many months (3). 
Huggins predicted that the genetic het-
erogeneity of outbred rat strains would 
make them better targets than inbred 
mouse strains for rapidly and consistently 
inducing mammary cancers.
He and two postdoctoral researchers 
began to administer 3-MC in various 
doses and for different time periods to 
various strains of female rats. To their 
surprise, a single high dose was suffi-
cient to induce detectable breast tumors 
within a month in all 682 of their 
group of Sprague-Dawley rats. Many 
of these carcinomas were hormone 
dependent and decreased in size after 
an injection of testosterone or removal 
of either the ovaries or the pituitary. 
Huggins published these breakthrough 
results in The Journal of Experimental 
Medicine in 1959 (4).
This model, which came to be 
known as the “Huggins tumor,” was 
the workhorse of breast cancer research 
for the next two decades. The mecha-
nisms that make 3-MC and other 
polycyclic compounds potent breast 
cancer inducers were only recently dis-
covered. Some of their metabolic by-
products activate the estrogen receptor 
(ER), and others alkylate DNA and dis-
rupt gene regulation in mammary cells.
Sorting out differences
Huggins used his model to show that 
only some cancers were hormone depen-
dent and could be cured by hormone 
deprivation (5). With Huggins’s encour-
agement, others at the center later identi-
fied ERs and showed that only breast 
tumors that expressed ERs responded 
well to surgical removal of the estrogen 
source (6). When this method failed 
in some ER-positive patients, Huggins 
treated their cancers with massive doses 
of progesterone and estradiol as large 
doses of these ovarian steroids were 
known to differentiate breast cells in vitro 
and decrease their cancer potential (7).
Branching out
Therapeutic treatment was not the only 
thing on the minds of those using the 
Huggins model. “We needed to treat not 
only women with the disease but also 
women who were at high risk for the 
disease,” says Craig Jordan, a director of 
research at the Fox Chase Cancer Center 
(Philadelphia, PA). In 1973, Jordan trav-
eled to Huggins’s laboratory to learn 
how the Huggins tumor model could 
be adapted for prevention purposes. His 
discovery that the failed contraceptive 
tamoxifen prevented hormone-driven 
cancer growth in these rats led to the use 
of this drug as a chemopreventive agent 
in pre- and post-menopausal women at 
high risk (8). Huggins’s discovery of the 
hormonal dependence of cancer cells in 
experimental animals thus contributed to 
solutions for both treatment and preven-
tion. He was awarded the Nobel Prize 
for Physiology or Medicine in 1966.
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